Lobsor Pharmaceuticals AB is acquired by STADA Arzneimittel AG [Back Bay Transaction]

Back Bay Life Science Advisors' investment banking team is proud to announce that we served as strategic and financial advisor to Swedish-based Lobsor Pharmaceuticals, initiating and executing its sale to STADA Arzneimittel.

As part of the transaction, STADA has acquired global rights ex-Americas and Japan to an innovative therapy for advanced Parkinson’s Disease currently being commercialized across Europe.

Back Bay Life Science Advisors has supported Lobsor for many years through numerous strategic, development, and commercialization considerations. Our model of fully integrated strategic advisory and investment banking continues to support and enable our clients to achieve their goals in advancing therapies and realizing stakeholder value, especially during these challenging times.

Our warmest congratulations to Lobsor and STADA for their newly combined strength in addressing a great unmet need in advanced Parkinson’s patients.

LEARN MORE AND READ THE LOBSOR-STADA ANNOUNCEMENT >